A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint inhibitors experience increased susceptibility to common infections.

Researchers from the Josep Carreras Leukaemia Research Institute, led by Dr. Manel Esteller, have published a dataset covering thousands of methylated sites from hundreds of cancer-derived cultured cells, covering many leukaemias, lymphomas and myelomas, from humans and mice. With this data, any researcher can access the epigenetic signature of these tumours for research and clinical purposes. Researchers from the Josep Carreras Leukaemia Research Institute, led by Dr. Manel Esteller, have published a dataset covering thousands of methylated sites from hundreds of cancer-derived cultured cells, covering many leukaemias, lymphomas and myelomas, from humans and mice. With this data, any researcher can access the epigenetic signature of these tumours for research and clinical purposes.